Katherine Fuh, MD, PhD


Katherine FuhI received my MD from Georgetown School of Medicine in 2005. Then, in 2013, I received my PhD in cancer biology from Stanford University. I am now an associate professor of obstetrics and gynecology at Washington University School of Medicine. My research focuses on identifying pathways involved in metastasis in the context of incorporating the tumor microenvironment of ovarian cancer. I am also interested in developing a human in mouse model in ovarian cancer.


Our lab focuses on developing new strategies for overcoming treatment resistance and preventing metastasis for ovarian and uterine cancers within the context of the tumor microenvironment. To do this, we utilize primary cells cultured from the omentum to re-create the microenvinroment and utilize this model system to improve treatment in parp inhibitors, carboplatin, paclitaxel, and immunotherapy.

Recent publications

Mullen, MM, Lomonosova E, Toboni MD, Oplt A, Cybulla E, Blachut B, Noia H, Wilke D, Rankin EB, Kuroki LM, Hagemann AR, Hagemann IS, McCourt CK, Thaker PH, Mutch DG, Powell MA, Mosammaparast N, Vindigni A, Fuh KC. GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress. Accepted Molecular Cancer Research Sept 2021.

Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A. Homologous recombination deficiency real-time clinical assays, ready or not? Gynecol Oncol 2020 Dec;159(3):877-886. PMID: 32967790. 

Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck H, Hagemann IS, Hagemann AR, McCourt CM, Thaker PH, Powell MA, Mutch DG, Fuh KC. Therapeutic inhibition of the receptor tyrosine kinase AXL improves sensitivity to platinum and taxane in ovarian cancer. Molecular Cancer Therapeutics 2019 Feb; 18(2); 389-398.  PMID: 30478151.

Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. Molecular Cancer Therapeutics 2017 Dec; 16(12): 2881-2891. PMID: 28904132.

Grither WR, Divine LM, Meller EH, Wilke DJ, Desai RA, Loza AJ, Zhao P, Lohrey A, Longmore GD, Fuh KC. TWIST1 induces expression of Discoidin DomainReceptor2 (DDR2) to Promote Ovarian Cancer Metastasis. Oncogene 2018 Mar; 37(13): 1714- 1729. PMID: 29348456.